Fulgent Genetics Inc (FLGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 164,656 | 153,557 | 506,239 | 402,562 | 280,338 |
| Depreciation Amortization | 16,263 | 6,605 | 18,600 | 13,003 | 7,511 |
| Income taxes - deferred | -7,639 | -5,497 | -8,188 | -6,574 | -3,055 |
| Accounts receivable | 1,802 | -32,924 | 42,300 | 65,003 | 32,460 |
| Accounts payable and accrued liabilities | -10,258 | 2,110 | -12,206 | -9,002 | -10,256 |
| Other Working Capital | -9,747 | 14,816 | -2,676 | 39,074 | 17,107 |
| Other Operating Activity | 44,460 | 49,744 | -5,492 | -42,575 | -14,815 |
| Operating Cash Flow | $199,537 | $188,411 | $538,577 | $461,491 | $309,290 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -175,056 | -102,373 | -710,490 | -462,423 | -390,269 |
| PPE Investments | -8,600 | -5,346 | -23,749 | -17,807 | -14,414 |
| Net Acquisitions | -137,755 | N/A | -61,868 | -61,868 | -18,509 |
| Purchase Of Investment | -15,000 | N/A | N/A | N/A | N/A |
| Sale Of Investment | 133,407 | 133,407 | 269,591 | 155,809 | 51,696 |
| Purchase Sale Intangibles | N/A | N/A | -32 | N/A | N/A |
| Other Investing Activity | -10,000 | -25,000 | -20,032 | -20,000 | 0 |
| Investing Cash Flow | $-213,004 | $688 | $-546,548 | $-406,289 | $-371,496 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 58 |
| Debt Repayment | -598 | -456 | -11 | -3 | N/A |
| Common Stock Issued | 19 | 16 | 89,561 | 75,711 | 75,724 |
| Common Stock Repurchased | -11,507 | -494 | -4,155 | -3,467 | -552 |
| Other Financing Activity | 0 | 0 | 10 | 10 | 10 |
| Financing Cash Flow | $-12,086 | $-934 | $85,405 | $72,251 | $75,240 |
| Exchange Rate Effect | -561 | 10 | 34 | -2 | 1 |
| Beginning Cash Position | 164,894 | 164,894 | 87,426 | 87,426 | 87,426 |
| End Cash Position | 138,780 | 353,069 | 164,894 | 214,877 | 100,461 |
| Net Cash Flow | $-26,114 | $188,175 | $77,468 | $127,451 | $13,035 |
| Free Cash Flow | |||||
| Operating Cash Flow | 199,537 | 188,411 | 538,577 | 461,491 | 309,290 |
| Capital Expenditure | -8,618 | -5,360 | -23,812 | -17,829 | -14,427 |
| Free Cash Flow | 190,919 | 183,051 | 514,765 | 443,662 | 294,863 |